Europe’s drug regulator is evaluating South Korean drugmaker Celltrion’s Covid-19 antibody treatment, the third such drug against the disease to go under real-time review in the region.

Regeneron and Sanofi’s checkpoint inhibitor Libtayo (cemiplimab-rwlc) won U.S. Food and Drug Administration approval for the first-line treatment of patients with advanced non-small cell lung cancer whose tumors have high PD-L1 expression.

The U.S. Food and Drug Administration granted Emergency Use Authorization (EUA) to a combination of Eli Lilly and AbCellera’s monoclonal antibody bamlanivimab and the Lilly antibody etesevimab for mild to moderate Covid-19.

BeiGene announced topline data for tislelizumab for esophageal squamous cell carcinoma (ESCC), the anti-PD-1 monoclonal antibody’s fourth positive Phase III trial.

Protecting the most vulnerable, Eli Lilly’s bamlanivimab significantly reduced Covid-19 risk for nursing home residents in a Phase III trial. 

Larger clinical trials are needed to assess whether Roche’s Actemra (tocilizumab) can cut death rates among the sickest Covid-19 patients after a small study found the arthritis drug was no better than standard care in severe cases.

The new Covid-19 variant identified in South Africa can evade the antibodies that attack it in treatments using blood plasma from previously recovered patients, and may reduce the efficacy of the current line of vaccines, according to scientists.

French pharma giant Sanofi kicked off 2021 with a $1.4 billion cash acquisition of U.K.-based Kymab to bolster the company’s presence in immunology.

The U.S. Food and Drug Administration approved GlaxoSmithKline plc’s Benlysta (belimumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.

U.S. hospitals have been slow to embrace Covid-19 antibody drugs from Eli Lilly and Co. and Regeneron Pharmaceuticals Inc. that were authorized to reduce the risk of hospitalization, U.S. officials said.